Use of drug conjugate in treating tumor disease and method therefor
Coupling of anti-Trop-2 monoclonal antibodies with small molecule cytotoxins through biologically active conjugates, tumor-specific killing is achieved for refractory and recurrent tumors such as non-small cell lung cancer, and existing chemotherapy is solved The problems of insufficient efficacy of the drug and major side effects have significantly improved the therapeutic effect and reduced toxicity.
Patent Information
- Application Number
- PCT/CN2024/093937
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-22
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
Existing chemotherapy drugs are ineffective in refractory and recurrent tumors such as non-small cell lung cancer and have great side effects, and more targeted and safe treatments are needed.
Using biologically active conjugates, by coupling anti-Trop-2 monoclonal antibodies with small molecule cytotoxins, the targeting properties of the antibodies are used to introduce toxins into target cells, and tumor-specific killing is achieved, and prepared as formula (I) ) The biologically active conjugates shown in the treatment of locally advanced or metastatic solid tumors that fail standard treatment or have no standard treatment regimen.
It improves the therapeutic effectiveness of refractory and recurrent tumors, reduces toxicity to normal cells, significantly reduces tumor volume, and shows good safety and tolerance in clinical trials.
Smart Images

Figure PCTCN2024093937-FTAPPB-I100001 
Figure PCTCN2024093937-FTAPPB-I100002 
Figure PCTCN2024093937-FTAPPB-I100003
Abstract
Description
Uses and methods of drug conjugates in treating tumor diseases
[0001] This application is based on the application with CN application number 202310579893.9 and application date May 22, 2023, and claims its priority. The disclosed content of the CN application is hereby introduced as a whole into this application. Technical Field
[0002] The present application relates to the use and methods of drug conjugates for treating tumor diseases, in particular, for treating locally advanced or metastatic solid tumors that are refractory to existing standard treatment and cannot be surgically resected, such as tumors that have failed and / or recurred after first-line chemotherapy, tumors that have failed and / or recurred after radiotherapy, and / or tumors that have failed and / or recurred after targeted drug therapy, in particular non-small cell lung cancer. Background Art
[0003] Cancer is a significant global public health burden. In the United States, cancer remains the second leading cause of death after cardiovascular disease; in China, cancer incidence is also on the rise. In 2019, the number of new malignant tumor cases in China was approximately 4.4 million, and the number of deaths was approximately 2.624 million. The continued rise in cancer incidence and deaths will lead to an overall expansion in the oncology treatment market.
[0004] Chemotherapy is one of the mainstays of cancer treatment, but traditional chemotherapy drugs lack tumor recognition specificity and can easily harm normal cells, leading to serious adverse reactions in patients. To improve the survival rate of cancer patients, innovations in treatment approaches are urgently needed to complement advances in detection and diagnosis. Despite significant progress in many indications, the mortality rate for some of the most difficult-to-treat solid tumors has not improved significantly since the 1970s, and more effective treatments with fewer side effects are still needed. Molecularly targeted drugs are an important area of current drug design.
[0005] Monoclonal antibody drugs have advantages such as strong targeting, high specificity, and a low incidence of serious adverse reactions, but their large molecular weight limits the effectiveness of single-drug treatment. ADC drugs (Antibody-drug conjugates) are a class of drugs that couple monoclonal antibodies and other substances to varying numbers of small molecule cytotoxins (effector molecules) through chemical linkers. Once the ADC molecules enter the body, they can bind to antigens on the surface of target cells through the guidance of the monoclonal antibodies and enter the target cells. The ADC molecules inside the cells can release effector molecules through chemical and / or enzymatic reactions to achieve the purpose of destroying the target cells. ADC drugs combine the advantages of strong targeting of monoclonal antibodies with the high activity of small molecule toxins, which can not only reduce the toxic side effects of small molecule cytotoxins, but also improve the efficacy of the drugs.
[0006] Currently, many ADC drugs are marketed worldwide, with indications covering leukemia, lymphoma, breast cancer, and other diseases. However, some ADC drugs still have certain issues in terms of pharmacokinetic properties and safety, which may lead to serious adverse reactions in patients after use. The therapeutic efficacy of some metastatic, recurrent, and / or refractory cancers also needs to be further improved. Therefore, there is still a need to develop uses or treatment methods for ADC drugs to treat these metastatic, recurrent, and / or refractory cancers, maximize their effectiveness and minimize their toxicity, so as to meet the medication needs of cancer patients.
[0007] Summary of the Invention
[0008] The present invention provides the use of a bioactive conjugate represented by formula (I) in the preparation of a medicament for treating individuals suffering from tumor diseases, particularly individuals suffering from recurrent or refractory locally advanced or metastatic non-small cell lung cancer;
[0009] {D-[L1-(L2) m1 -(L3) m2 -(L4) m3 -E]} γ -A
[0010] Formula (I)
[0011] in,
[0012] L1 is Each R1 and R2 are independently hydrogen (such as protium or deuterium), halogen, carboxylic acid group, sulfonic acid group, cyano group, C 1-6 Alkyl, halogenated C 1-6 Alkyl, cyano substituted C 1-6 Alkyl (e.g. -CH2CN), C 1-6 Alkoxy, C 2-10 Alkenyl or C 2-10 Alkynyl; Z1 is an amino acid or a peptide composed of 2-10 amino acids; x1 and x2 are each independently 0, 1, 2, 3, 4, 5 or 6; and the 1 position of L1 is connected to D, and the 2 position of L1 is connected to L2;
[0013] L2 is Wherein, y1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and the 1 position of L2 is connected to L1, and the 2 position of L2 is connected to L3;
[0014] L3 is a 5-12 membered heteroaromatic ring;
[0015] L4 is Where Z2 is selected from C 1-6 Alkylene, C 2-10 Alkenylene, C 2-10 Alkynylidene, and C3-8 Cycloalkylene; R3 is selected from H and C 1-6 Alkyl; Z3 does not exist or is C 1-6 Alkylene; or, R3 and Z3 together with the nitrogen atom to which they are attached form a 4-8 membered heterocyclic group; α is 0, 1, 2, 3, 4, 5 or 6, and the 2 position of L4 is connected to E, and the 1 position of L4 is connected to L3;
[0016] E is wherein each R4 is independently hydrogen (e.g., protium or deuterium), β is 0, 1, or 2, and the 2 position of E is connected to A (e.g., connected to the thiol group on A), and the 1 position of E is connected to L4;
[0017] m1, m2 and m3 are each independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10;
[0018] D is a bioactive molecular fragment;
[0019] γ refers to {D-[L1-(L2) m1 -(L3) m2 -(L4) m3 -E]} number of moieties, which is selected from an integer between 1 and 10; preferably, γ is selected from an integer between 3 and 8 (e.g., 3, 4, 5, 6, 7 or 8);
[0020] A is an anti-Trop-2 monoclonal antibody or an antigen-binding fragment thereof.
[0021] In some embodiments, the tumor disease is an unresectable locally advanced or metastatic solid tumor that has failed standard treatment, or has no standard treatment options, or is not currently suitable for standard treatment. In some embodiments, the standard treatment refers to the standard treatment options for the tumor disease recommended by the NCCN guidelines and the CSCO diagnosis and treatment guidelines.
[0022] In some embodiments, the tumor disease is a tumor that has failed and / or relapsed after first-line chemotherapy. In some embodiments, the first-line chemotherapy drug refers to a first-line chemotherapy drug for the tumor disease recommended by the NCCN Guidelines and the CSCO Diagnosis and Treatment Guidelines.
[0023] In some embodiments, the tumor disease is a tumor that has failed and / or recurred after radiotherapy. In some embodiments, the radiotherapy refers to a radiotherapy regimen for the tumor disease recommended by the NCCN guidelines and the CSCO diagnosis and treatment guidelines.
[0024] In some embodiments, the tumor disease is a tumor that has failed and / or recurred after treatment with a targeted drug or immunotherapy. In some embodiments, the targeted drug or immunotherapy refers to a targeted drug or immunotherapy for the tumor disease recommended by the NCCN Guidelines and the CSCO Diagnosis and Treatment Guidelines.
[0025] In some embodiments, the tumor disease includes but is not limited to breast cancer, gastric cancer, lung cancer, ovarian cancer, urothelial cancer, esophageal cancer, liver cancer, colorectal cancer, cervical cancer, endometrial cancer, pancreatic cancer, bladder cancer, or brain tumor; preferably, it is breast cancer (such as triple-negative breast cancer or Her2-positive breast cancer), ovarian cancer (such as ovarian epithelial cancer), gastric cancer, lung cancer, pancreatic cancer, bladder cancer, or urothelial cancer; more preferably, the tumor disease is triple-negative breast cancer, Her2-positive breast cancer, ovarian cancer, gastric cancer, lung cancer or pancreatic cancer; further preferably, the tumor disease is triple-negative breast cancer, Her2-positive breast cancer, ovarian cancer or gastric cancer.
[0026] In some embodiments, the neoplastic disease is breast cancer.
[0027] In some embodiments, the breast cancer includes but is not limited to the following types: Luminal A, Luminal B, Her2-positive, triple-negative, or HR+ / Her2- breast cancer.
[0028] In some embodiments, the breast cancer includes but is not limited to the following types: Luminal A, Luminal B, Her2-positive, and triple-negative.
[0029] In some embodiments, the tumor disease is triple-negative breast cancer.
[0030] In some embodiments, the tumor disease is Her2-positive breast cancer.
[0031] In some embodiments, the tumor disease is HR+ / Her2- breast cancer.
[0032] In some embodiments, the neoplastic disease is ovarian cancer.
[0033] In some embodiments, the ovarian cancer includes but is not limited to the following types: platinum-sensitive type and platinum-resistant type.
[0034] In some embodiments, the tumor disease is gastric cancer.
[0035] In some embodiments, the gastric cancer includes but is not limited to the following types: adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, undifferentiated carcinoma, and neuroendocrine tumor.
[0036] In some embodiments, the neoplastic disease is pancreatic cancer.
[0037] In some embodiments, the pancreatic cancer includes but is not limited to the following types: epithelial tumors, exocrine tumors, borderline tumors, ductal adenocarcinomas, endocrine tumors, mature teratomas, mesenchymal tumors, malignant lymphomas, and secondary tumors.
[0038] In some embodiments, the neoplastic disease is bladder cancer.
[0039] In some embodiments, the bladder cancer includes, but is not limited to, the following types: urothelial (transitional cell) carcinoma, squamous cell carcinoma, and adenocarcinoma.
[0040] In some embodiments, the neoplastic disease is urothelial carcinoma.
[0041] In some embodiments, the urothelial carcinoma includes, but is not limited to, the following types: basal-like, luminal-like, and wild-type.
[0042] In some embodiments, the neoplastic disease is lung cancer.
[0043] In some embodiments, the lung cancer includes but is not limited to the following types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
[0044] In some embodiments, the lung cancer is relapsed or refractory locally advanced or metastatic non-small cell lung cancer.
[0045] In some embodiments, the lung cancer is EGFR wild-type non-small cell lung cancer.
[0046] In some embodiments, the individual with EGFR wild-type non-small cell lung cancer has previously received a median of 2 lines of therapy.
[0047] In some embodiments, the individual with EGFR wild-type non-small cell lung cancer has previously received platinum-containing chemotherapy combined with anti-PD-1 / L1 monoclonal antibody therapy.
[0048] In some embodiments, the lung cancer is non-small cell lung cancer carrying an EGFR mutation.
[0049] In some embodiments, the NSCLC carrying an EGFR mutation includes an exon 19 deletion or an exon 21 L858R mutation.
[0050] In some embodiments, the NSCLC individual carrying the EGFR mutation has previously received treatment with a first-generation or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and, after treatment failure, tumor biopsy confirmed that the exon 20 T790M mutation is negative, or the NSCLC individual carrying the EGFR mutation has previously received treatment with a third-generation EGFR-TKI (regardless of the T790M mutation status).
[0051] In some embodiments, the non-small cell lung cancer carrying an EGFR mutation is resistant to EGFR-TKI treatment.
[0052] In some embodiments, the conjugate has the following structure:
[0053] L1 is selected from And the 1 position of L1 is connected to D, and the 2 position of L1 is connected to L2;
[0054] L2 is wherein y1 is 3, 4, 5, 6, 7, 8, 9 or 10; and the 1 position of L2 is connected to L1, and the 2 position of L2 is connected to L3;
[0055] L3 is selected from a 5-6 membered heteroaromatic ring, such as pyrazole or triazole;
[0056] L4 is Where Z2 is selected from C 1-3 Alkylene; R3 is H; Z3 is selected from C 1-3 Alkylene; α is 0, and the 2-position of L4 is connected to E, and the 1-position of L4 is connected to L3;
[0057] E is wherein each R4 is independently hydrogen (e.g., protium or deuterium), β is 0, 1, or 2, and the 2 position of E is connected to A (e.g., connected to the thiol group on A), and the 1 position of E is connected to L4;
[0058] m1, m2, and m3 are all 1;
[0059] The bioactive molecule is selected from Preferably, the bioactive molecule is linked to the 1 position of L1 via its own hydroxyl group;
[0060] γ is selected from an integer between 3 and 8 (e.g., 3, 4, 5, 6, 7, or 8);
[0061] A is sacituzumab or an antigen-binding fragment thereof.
[0062] In some embodiments, the conjugate has the following structure:
[0063] L1 is selected from And the 1 position of L1 is connected to D, and the 2 position of L1 is connected to L2;
[0064] L2 is wherein y1 is 3, 4, 5, 6, 7, 8, 9 or 10; and the 1 position of L2 is connected to L1, and the 2 position of L2 is connected to L3;
[0065] L3 is selected from a 5-6 membered heteroaromatic ring, such as pyrazole or triazole;
[0066] L4 is Where Z2 is selected from C 1-3 Alkylene; R3 is H; Z3 is selected from C 1-3 Alkylene; α is 1, and the 2-position of L4 is connected to E, and the 1-position of L4 is connected to L3;
[0067] E is wherein each R4 is independently hydrogen (e.g., protium or deuterium), β is 0, 1, or 2, and the 2 position of E is connected to A (e.g., connected to the thiol group on A), and the 1 position of E is connected to L4;
[0068] m1, m2, and m3 are all 1;
[0069] The bioactive molecule is selected from Preferably, the bioactive molecule is linked to the 1 position of L1 via its own hydroxyl group;
[0070] γ is selected from an integer between 3 and 8 (e.g., 3, 4, 5, 6, 7, or 8);
[0071] A is sacituzumab or an antigen-binding fragment thereof.
[0072] In some embodiments, D is selected from
[0073] In some technical solutions, the conjugate is a conjugate A having the structure shown in the following formula:
[0074] Wherein, γ is an integer of 1-10; preferably, γ is an integer selected from 5-8.
[0075] The present invention provides uses of compositions comprising bioactive conjugates of formula (I) as described herein. The bioactive conjugate compositions described herein have a DAR of about 1 to about 10 or any subrange therebetween, for example: about 1 to 2, about 1 to 3, about 1 to 4, about 1 to 5, about 1 to 6, about 1 to 7, about 1 to 8, about 1 to 9, about 1 to 10, about 2 to 3, about 2 to 4, about 2 to 5, about 2 to 6, about 2 to 7, about 2 to 8, about 2 to 9, about 2 to 10, about 3 to 4, about 3 to 5 , about 3 to 6, about 3 to 7, about 3 to 8, about 3 to 9, about 3 to 10, about 4 to 5, about 4 to 6, about 4 to 7, about 4 to 8, about 4 to 9, about 4 to 10, about 5 to 6, about 5 to 7, about 5 to 8, about 5 to 9, about 5 to 10, about 6 to 7, about 6 to 8, about 6 to 9, about 6 to 10, about 7 to 8, about 7 to 9, about 7 to 10, about 8 to 9, about 8 to 10 or about 9 to 10.
[0076] In certain embodiments, the DAR of the composition of the bioactive conjugate described herein is about 3 to 9, e.g., about 3.0 to 3.5, about 3.0 to 4.0, about 3.0 to 4.5, about 3.0 to 5.0, about 3.0 to 6.0, about 3.5 to 4.0, about 3.5 to 4.5, about 3.5 to 5.0, about 3.5 to 5.5, about 3.5 to 6.0, about 3.5 to 6.5, about 4.0 to 4.5, about 4.0 to 5.0, about 4.0 to 5.5, about 4.0 to 6.0, about 4.0 to 6.5, about 4.0 to 7.0, about 4.0 to 7.0, about 4.0 to 7.5 ... 0 to 8.0, about 4.5 to 5.0, about 4.5 to 5.5, about 4.5 to 6.0, about 4.5 to 6.5, about 4.5 to 7.0, about 4.5 to 7.5, about 5.0 to 8.0, about 5.5 to 6.0, about 5.5 to 6.5, about 5.5 to 7.0, about 5.5 to 7.5, about 5.5 to 8.0, about 6.0 to 6.5, about 6.0 to 7.0, about 6.0 to 7.5, about 6.0 to 8.5, about 6.5 to 7.0, about 6.5 to 7.5, about 6.5 to 8.5, about 7.0 to 7.5.
[0077] In some embodiments, the DAR value of the composition of the bioactive conjugate described herein is about 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, or 8.0.
[0078] In another aspect, the present invention provides a method for treating tumor diseases, particularly relapsed or refractory non-small cell lung cancer, comprising administering to an individual in need thereof a therapeutically effective amount of a bioactive conjugate of formula (I) as described above and / or a pharmaceutical composition comprising the bioactive conjugate of formula (I).
[0079] In some embodiments, the tumor disease is an unresectable locally advanced or metastatic solid tumor that has failed standard treatment, or has no standard treatment options, or is not currently suitable for standard treatment. In some embodiments, the standard treatment refers to the standard treatment options for the tumor disease recommended by the NCCN guidelines and the CSCO diagnosis and treatment guidelines.
[0080] In some embodiments, the tumor disease is a tumor that has failed and / or relapsed after first-line chemotherapy. In some embodiments, the first-line chemotherapy drug refers to a first-line chemotherapy drug for the tumor disease recommended by the NCCN Guidelines and the CSCO Diagnosis and Treatment Guidelines.
[0081] In some embodiments, the tumor disease is a tumor that has failed and / or recurred after radiotherapy. In some embodiments, the radiotherapy refers to a radiotherapy regimen for the tumor disease recommended by the NCCN guidelines and the CSCO diagnosis and treatment guidelines.
[0082] In some embodiments, the tumor disease is a tumor that has failed and / or recurred after treatment with a targeted drug or immunotherapy. In some embodiments, the targeted drug or immunotherapy refers to a targeted drug or immunotherapy for the tumor disease recommended by the NCCN Guidelines and the CSCO Diagnosis and Treatment Guidelines.
[0083] In some embodiments, the tumor disease includes but is not limited to breast cancer, gastric cancer, lung cancer, ovarian cancer, urothelial cancer, esophageal cancer, liver cancer, colorectal cancer, cervical cancer, endometrial cancer, pancreatic cancer, bladder cancer, or brain tumor; preferably, it is breast cancer (such as triple-negative breast cancer or Her2-positive breast cancer), ovarian cancer (such as ovarian epithelial cancer), gastric cancer, lung cancer, pancreatic cancer, bladder cancer, or urothelial cancer; more preferably, the tumor disease is triple-negative breast cancer, Her2-positive breast cancer, ovarian cancer, gastric cancer, lung cancer or pancreatic cancer; further preferably, the tumor disease is triple-negative breast cancer, Her2-positive breast cancer, ovarian cancer or gastric cancer.
[0084] In some embodiments, the neoplastic disease is breast cancer.
[0085] In some embodiments, the breast cancer includes but is not limited to the following types: Luminal A, Luminal B, Her-2 positive, and triple negative.
[0086] In some embodiments, the tumor disease is triple-negative breast cancer.
[0087] In some embodiments, the tumor disease is Her2-positive breast cancer.
[0088] In some embodiments, the tumor disease is HR-positive and Her2-negative breast cancer (HR+ / Her2- breast cancer).
[0089] In some embodiments, the neoplastic disease is ovarian cancer.
[0090] In some embodiments, the ovarian cancer includes but is not limited to the following types: platinum-sensitive type and platinum-resistant type.
[0091] In some embodiments, the tumor disease is gastric cancer.
[0092] In some embodiments, the gastric cancer includes but is not limited to the following types: adenocarcinoma, adenosquamous carcinoma, squamous cell carcinoma, undifferentiated carcinoma, and neuroendocrine tumor.
[0093] In some embodiments, the neoplastic disease is pancreatic cancer.
[0094] In some embodiments, the pancreatic cancer includes but is not limited to the following types: epithelial tumors, exocrine tumors, borderline tumors, ductal adenocarcinomas, endocrine tumors, mature teratomas, mesenchymal tumors, malignant lymphomas, and secondary tumors.
[0095] In some embodiments, the neoplastic disease is bladder cancer.
[0096] In some embodiments, the bladder cancer includes, but is not limited to, the following types: urothelial (transitional cell) carcinoma, squamous cell carcinoma, and adenocarcinoma.
[0097] In some embodiments, the neoplastic disease is urothelial carcinoma.
[0098] In some embodiments, the urothelial carcinoma includes, but is not limited to, the following types: basal-like, luminal-like, and wild-type.
[0099] In some embodiments, the neoplastic disease is lung cancer.
[0100] In some embodiments, the lung cancer includes but is not limited to the following types: small cell lung cancer and non-small cell lung cancer.
[0101] In some embodiments, the lung cancer is relapsed or refractory locally advanced or metastatic non-small cell lung cancer.
[0102] In some embodiments, the lung cancer is EGFR wild-type non-small cell lung cancer.
[0103] In some embodiments, the individual with EGFR wild-type non-small cell lung cancer has previously received a median of 2 lines of therapy.
[0104] In some embodiments, the individual with EGFR wild-type non-small cell lung cancer has previously received platinum-containing chemotherapy combined with anti-PD-1 / L1 monoclonal antibody therapy.
[0105] In some embodiments, the lung cancer is non-small cell lung cancer carrying an EGFR mutation.
[0106] In some embodiments, the NSCLC carrying an EGFR mutation includes an exon 19 deletion or an exon 21 L858R mutation.
[0107] In some embodiments, the NSCLC individual carrying the EGFR mutation has previously received treatment with a first- or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) and, after treatment failure, was confirmed negative for the exon 20 T790M mutation by tumor biopsy, or the NSCLC individual carrying the EGFR mutation has previously received treatment with a third-generation EGFR-TKI (regardless of the T790M mutation status).
[0108] In some embodiments, the non-small cell lung cancer carrying an EGFR mutation is resistant to EGFR-TKI treatment.
[0109] In some embodiments, the individual is an individual with relapsed or refractory locally advanced or metastatic non-small cell lung cancer or other tumors.
[0110] In some embodiments, the individual is an individual with EGFR wild-type non-small cell lung cancer, or an individual with EGFR mutation-resistant non-small cell lung cancer.
[0111] In some embodiments, the method of treating a tumor disease further comprises evaluating the tumor based on RECIST 1.1.
[0112] In some embodiments, the evaluation period is 6-8 weeks, for example 8 weeks.
[0113] In some embodiments, the pharmaceutical composition comprises the bioactive substance conjugate and a pharmaceutically acceptable carrier and / or excipient.
[0114] In some embodiments, the bioactive conjugate or the pharmaceutical composition is administered once every 7-35 days, preferably once every 7-28 days, for example, once every 7 days, 14 days, 21 days, 28 days, or 35 days.
[0115] In some embodiments, the bioactive substance conjugate or the pharmaceutical composition is administered once every 14 days.
[0116] In some embodiments, the conjugate or pharmaceutical composition is administered orally, transdermally, rectally, transmucosally, intramuscularly, intramedullary, intravenously, or intraperitoneally, preferably intravenously.
[0117] In some embodiments, the dosage of the bioactive substance conjugate per administration is 1 mg / kg to 30 mg / kg based on the individual's body weight; preferably 1 mg / kg to 20 mg / kg; more preferably 2 mg / kg to 12 mg / kg; further preferably 2-5 mg / kg, 4-7 mg / kg, 6-9 mg / kg, 8-11 mg / kg, 10-13 mg / kg, or 12-15 mg / kg; for example: 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 3.5 mg / kg, 4 mg / kg, 4.5 mg / kg, 5 mg / kg, 5.5 mg / kg, 6 mg / kg, 6.5 mg / kg, 7 mg / kg, 7.5 mg / kg, 8 mg / kg, 8.5 mg / kg, 9 mg / kg, 9.5 mg / kg, 10 mg / kg, 11 mg / kg or 12 mg / kg.
[0118] In some embodiments, the dosage of the bioactive substance conjugate administered per administration is 4 mg / kg or 5 mg / kg based on the individual's body weight.
[0119] In some embodiments, the dosage of the bioactive substance conjugate or the composition thereof is 1 mg / kg to 20 mg / kg based on the individual's body weight, and is administered once every 7-28 days.
[0120] In some embodiments, the lung cancer is EGFR wild-type non-small cell lung cancer, or non-small cell lung cancer that carries an EGFR mutation and is resistant to EGFR-TKI treatment.
[0121] In some embodiments, the lung cancer is EGFR wild-type non-small cell lung cancer, or non-small cell lung cancer carrying an EGFR mutation and resistant to EGFR-TKI treatment, and the dosage of the bioactive substance conjugate or its composition is 5 mg / kg based on the individual's body weight, administered once every 2 weeks.
[0122] In some embodiments, the administration regimen of the bioactive conjugate is divided into one or more administration phases (e.g., one phase, two phases, three phases, or four phases), and the administration cycle and administration dose of each phase are independently selected from the administration cycles or doses described above. In some embodiments, the use or method of the present invention causes tumor elimination or volume reduction.
[0123] In some embodiments, the uses or methods of the present invention result in a reduction in tumor volume of at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, or at least 40%.
[0124] In another aspect, the present invention provides a bioactive conjugate or composition represented by formula (I) for use in treating tumor diseases. The bioactive conjugate or composition and the tumor disease are as described above.
[0125] definition
[0126] Unless otherwise defined below, all technical and scientific terms used herein are intended to have the same meaning as those commonly understood by those skilled in the art. References to technology used herein are intended to refer to technology commonly understood in the art, including variations of technology or substitutions of equivalent technology that would be apparent to those skilled in the art. While it is believed that the following terms are well understood by those skilled in the art, the following definitions are set forth to better explain the present invention.
[0127] The drug-antibody conjugate ratio (DAR) refers to the average loading of the antibody to the small molecule toxin drug in the conjugate. Although the ratio of the small molecule toxin drug portion to the antibody portion has a specific value for a specific conjugate molecule, it should be understood that when used to describe a sample containing many molecules, this value refers to the average calculated based on the percentage of different specific conjugate molecules, and this loading average is referred to herein as the average conjugate ratio or "DAR".
[0128] The term "subject" refers to a mammal, such as a primate mammal, such as a human. In some embodiments, the individual (eg, human) has a tumor or cancer described herein, or is at risk of having the tumor or cancer.
[0129] The NCCN guidelines refer to the clinical practice guidelines for various malignant tumors issued by the National Comprehensive Cancer Network of the United States.
[0130] CSCO diagnosis and treatment guidelines refer to the clinical diagnosis and treatment guidelines for various malignant tumors issued by the Chinese Society of Clinical Oncology (CSCO).
[0131] The term "platinum-based chemotherapy" refers to chemotherapy using a platinum drug selected from cisplatin, carboplatin, cyclothiaplatin, nedaplatin, oxaliplatin, lobaplatin, satraplatin, miboplatin, enloplatin, iproplatin or dicycloplatin.
[0132] "First-generation EGFR-TKI inhibitors" include, for example, erlotinib or gefitinib. "Second-generation EGFR-TKI inhibitors" include, for example, afatinib or Vizimpro (dacomitinib). "Third-generation EGFR-TKI inhibitors" include, for example, osimertinib, rociletinib, omotinib, or AC0010.
[0133] The objective response rate (ORR) refers to the proportion of patients whose tumors shrink to a certain degree and for a certain period of time, including both complete response (CR) and partial response (PR). Objective response was assessed using the response evaluation criteria in solid tumors version 1.1 (RECIST 1.1). Patients must have measurable tumor lesions at baseline. Efficacy was assessed according to RECIST 1.1 as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD).
[0134] Disease progression (PD): The minimum value of the sum of all target lesion diameters measured during the entire study is used as a reference, and the relative increase in the sum of diameters is at least 20% (if the baseline measurement value is the minimum, the baseline value is used as a reference); in addition, the absolute value of the sum of diameters must increase by at least 5 mm (the appearance of one or more new lesions is also considered disease progression).
[0135] Stable disease (SD): The target lesion has not decreased to the level of PR, nor increased to the level of PD, but is somewhere in between. The minimum sum of the diameters can be used as a reference for research.
[0136] Partial response (PR): at least a 30% reduction in the sum of target lesions compared to baseline.
[0137] Complete remission (CR): All target lesions disappear and the short diameter of all pathological lymph nodes (including target nodules and non-target nodules) must be reduced to <10mm.
[0138] Disease control rate (DCR) is the percentage of cases with disease remission (including complete remission and partial remission, PR+CR) and stable disease (SD) after treatment among the evaluable cases, and the RECIST standard is maintained for at least 4 weeks.
[0139] Duration of response (DoR) refers to the time from the first assessment of CR or PR to the first assessment of PD or death from any cause.
[0140] Progression-free survival (PFS) is the time from randomization or first use of study drug to the first occurrence of disease progression or death from any cause.
[0141] Dose-limiting toxicities (DLT) are side effects of drugs that are the main reason for limiting further increase in drug dose.
[0142] Adverse Event (AE): refers to any untoward medical event that occurs in patients or clinical research subjects after receiving a drug, but is not necessarily causally related to the treatment.
[0143] Treatment-emergent adverse event (TEAE) refers to any AE that occurs or worsens during or after the first dose of the drug. BRIEF DESCRIPTION OF THE DRAWINGS
[0144] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of this application. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:
[0145] Figure 1 shows the conjugate A and the marketed drug Trodelvy TM In vitro plasma stability. DETAILED DESCRIPTION
[0146] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments and drawings. Obviously, the embodiments described are only some embodiments of the present invention, rather than all embodiments. The following description of at least one exemplary embodiment is actually only illustrative and in no way constitutes any limitation on the present invention and its application or use. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.
[0147] Example 1. 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hexan-5-amido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
[0148] Step 1: Synthesis of 6-(2-(methylsulfonyl)pyrimidin-5-yl)-N-(prop-2-yn-1-yl)hex-5-ynamide
[0149] Prop-2-yn-1-amine (189 mg, 3.4 mmol) and compound 3-4 (800 mg, 2.83 mmol) were dissolved in dichloromethane (10 mL) at 25°C. N,N-diisopropylethylamine (738 mg, 5.67 mmol) and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (1.63 g, 4.25 mmol) were added sequentially. The mixture was stirred for 2 h. The reaction solution was concentrated under reduced pressure, and the residue was purified on a flash silica gel column (ethyl acetate / petroleum ether = 3 / 1) to obtain the title compound, 700 mg. ESI-MS (m / z): 306.1 [M+H].
[0150] Step 2: Synthesis of 4-((S)-35-azido-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontanoylamino)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethanesulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-2H-pyrano[2,3-b]-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)carbonate
[0151] Under nitrogen at 25°C, T-030 (250 mg, 0.49 mmol) was dissolved in dichloromethane (10 mL), cooled to 0°C, and a solution of 4-dimethylaminopyridine (478 mg, 3.91 mmol) in dichloromethane (3 mL) was added. Then, a solution of triphosgene (72 mg, 0.24 mmol) in dichloromethane (10 mL) was slowly added dropwise. After the addition, the mixture was stirred at 0°C for 20 min, and the reaction solution was purged with nitrogen for 20 min. A solution of (S)-2-(3,2-azido-5-oxo-3,9,12,15,18,21,24,27,30-nonaoxa-6-azatriacetamido)-N-(4-(hydroxymethyl)phenyl)-6-(((4-methoxyphenyl)diphenylmethyl)amino)acetamide (518 mg, 0.49 mmol) in dichloromethane (7 mL) was added. The reaction mixture was stirred at 0°C for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by preparative HPLC to obtain the title compound, 500 mg. ESI-MS (m / z): 1597.5 [M+H].
[0152] Step 3: Synthesis of (S)-4-ethyl-11-(2-(N-isopropylmethylsulfonyl)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl(4-((S)-2-(4-(((4-methoxyphenyl)diphenylmethyl)amino)butyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hexane-5-amido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonyloxy-3,9-diazapentatriacontamido)benzyl)carbonate
[0153] Compound 33-1 (14 mg, 0.05 mmol) was dissolved in dimethyl sulfoxide and water (2.0 mL:0.5 mL) at room temperature. Cuprous bromide (11 mg, 0.08 mmol) was added and the mixture was stirred for 1 h. Purification by preparative HPLC afforded the title compound (30 mg). ESI-MS (m / z): 815.9 [(M-273) / 2+H]+.
[0154] Step 4: Synthesis of 4-((S)-2-(4-aminobutyl)-35-(4-((6-(2-(methylsulfonyl)pyrimidin-5-yl)hexane-5-amido)methyl)-1H-1,2,3-triazol-1-yl)-4,8-dioxo-6,12,15,18,21,24,27,30,33-nonaoxa-3,9-diazapentatriacontamido)benzyl((S)-4-ethyl-11-(2-(N-isopropylmethylsulfonamido)ethyl)-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)carbonate (Compound IM-1)
[0155] Compound 33-2 (30 mg, 0.02 mmol) was dissolved in dichloromethane (1.0 mL). Trifluoroacetic acid (0.2 mL) was added to the reaction mixture and allowed to react at room temperature for 30 min. Purification by preparative HPLC (Method C) afforded the trifluoroacetate salt of the title compound (20.0 mg). Its structural characterization is as follows:
[0156] 1H NMR (400MHz, DMSO-d6) δ10.18(s,1H),9.10(s,2H),8.38(t,J=5.56Hz,1H),8.32(d,J=8.40Hz,1H),8.22- 8.20(m,2H),8.09(t,J=5.68Hz,1H),7.91-7.87(m,2H),7.82-7.78(m,1H),7.69(brs,3H),7.61(d,J=8.5 6Hz,2H),7.32(d,J=8.56Hz,2H),7.06(s,1H),5.56(d,J=16.96Hz,1H),5.51(d,J=16.96Hz,1H),5.47(d, J=19.28Hz,1H),5.42(d,J=19.28Hz,1H),5.14(d,J=12.20Hz,1H),5.07(d,J=12.16Hz,1H),4.48(t,J=5. 24Hz,2H),4.46-4.43(m,1H),4.29(d,J=5.60Hz,2H),4.08-3.95(m,5H),3.79(t,J=5.28Hz,2H),3.51-3. 43(m,32H),3.40(s,3H),3.39-3.35(m,2H),3.30-3.26(m,2H),3.00(s,3H),2.82-2.74(m,2H),2.56(t,J =7.08Hz,2H),2.29(t,J=7.36Hz,2H),2.23-2.13(m,2H),1.82(p,J=7.24Hz,2H),1.78-1.63(m,2H),1.61 -1.49(m,2H),1.42-1.27(m,2H),1.15(d,J=6.80Hz,3H),1.13(d,J=6.76Hz,3H),0.90(t,J=7.32Hz,3H).
[0157] ESI-MS (m / z): 816.0 [M / 2 + H] + .
[0158] [α] D 20 The value is -19.55° (c = 1.000 g / 100 mL, CH3CN).
[0159] Example 2. Preparation of Conjugate A
[0160] 0.3 mL of sacituzumab antibody (anti-Trop-2, 33.5 mg / mL) was diluted with 0.25 mL of a solution containing 20 mM PB, 150 mM NaCl, and 20 mM sodium edetate (pH 7.6). 0.45 mL of a solution containing 20 mM PB and 150 mM NaCl (pH 7.6) was added and mixed thoroughly. The pH was adjusted to 7.4 with 1 M Na2HPO4 solution, and 10 mM TCEP (tris(2-carboxyethyl)phosphine) solution was added and mixed thoroughly. The mixture was allowed to stand at room temperature for 30 minutes. A 10-fold amount of IM-1 trifluoroacetate dissolved in dimethyl sulfoxide was added to the above solution, mixed thoroughly, and allowed to stand at room temperature for 2 hours. After completion, 6.1 μL of 100 mM cysteine was added to terminate the reaction. Finally, the buffer was exchanged with PBS buffer (pH 6.5) using a G-25 gel column to obtain the IM-1-sacituzumab antibody conjugate, designated Conjugate A.
[0161] The molecular weight of conjugate A was analyzed by LCMS. The measured molecular weights of the light and heavy chains of conjugate A were correlated with the theoretical molecular weights of light and heavy chains conjugated with different numbers of toxins. It was determined that each antibody molecule in conjugate A was conjugated with 1-10 toxins (i.e., γ was 1-10). The average coupling ratio (DAR) of approximately 6.9 was calculated based on the percentages of conjugate molecules conjugated with different numbers of toxins.
[0162] With reference to Example 2, conjugate A samples with DAR values ranging from 6 to 8 (eg, 7.3 or 7.4) were prepared in batches, and the following non-clinical and clinical studies were performed.
[0163] Example 3. Detection of the inhibitory effect of the conjugate on pancreatic cancer cell lines
[0164] use The effect of conjugate A on the proliferation of BxPC-3 cells (pancreatic cancer cell line, source: ATCC, TROP2-positive) was examined using a chemiluminescent cell viability assay (CTG). On day 1, BxPC-3 cells were harvested from the exponential growth phase, the cell suspension concentration was adjusted with culture medium, and the cells were plated in a 96-well cell culture plate at a final concentration of 2000 cells / well. The cells were cultured overnight in a 37°C, 5% CO2 incubator. On day 2, conjugate A (final concentrations of 0.152-1000 nM) was diluted 1:3 to a 10x working solution. 10 μl of the corresponding 10x working solution was added to each well. Three replicates were added for each drug concentration. After drug addition, the cells were incubated at 37°C, 5% CO2 for 72 hours. On the fifth day of the experiment, 50 μl (1 / 2 culture volume) of pre-melted and room temperature CTG solution was added to each well and mixed for 2 minutes using a microplate shaker. After standing at room temperature for 20 minutes, the fluorescence signal value was measured using an Envision 2104 plate reader.
[0165] The test results showed that conjugate A significantly inhibited the proliferation of TROP2 positive cells BxPC-3, and its IC 50 The maximum inhibition rate was 14.3 nM, and the maximum inhibition rate was 95.3%. This shows that conjugate A can inhibit the proliferation of TROP2-positive pancreatic cancer cells, suggesting that it has the effect of treating pancreatic cancer.
[0166] Example 4. Detection of the effects of conjugates on cardiovascular and respiratory function
[0167] The cynomolgus monkeys were divided into 10 groups (half male and half female) and the conjugate A was administered intravenously at doses of 25 mg / kg, 50 mg / kg, and 75 mg / kg, respectively, once every 2 weeks for a total of 4 times. The large animal non-invasive physiological signal telemetry system was used to detect the lead II electrocardiogram and respiratory rate, and the arterial blood pressure was measured with a non-invasive sphygmomanometer to evaluate the effects of conjugate A on the cardiovascular and respiratory function of the cynomolgus monkeys.
[0168] Results showed no arrhythmias in lead II electrocardiograms (ECGs) of monkeys in all groups receiving conjugate A before the first dose, 2-3 hours, 24-25 hours, 72-73 hours, and 7 days after dosing, approximately 2-3 hours after the final dose, and before the end of the recovery period. No significant abnormalities were observed in lead II ECG parameters, including heart rate, RR interval, P wave duration, PR interval, QRS duration, QT interval, and corrected QT interval, as well as in systolic blood pressure, diastolic blood pressure, mean arterial pressure, and respiratory rate. These findings suggest that conjugate A has no effects on the cardiovascular and respiratory systems of cynomolgus monkeys and has a promising clinical safety profile.
[0169] Example 5. Detection of toxic metabolic behavior of conjugates in animals
[0170] Cynomolgus monkeys were divided into four groups according to the dose level: control, 25 mg / kg, 50 mg / kg, and 75 mg / kg, with five males and five females in each group. At the 25 mg / kg and 50 mg / kg dose levels, the monkeys were intravenously injected with Conjugate A once every two weeks for four consecutive doses. Blood samples were collected from each group before the first and last doses, immediately after the dose (0-1 minute after the dose), 4 hours, 24 hours, 48 hours, 96 hours, and 168 hours after the first and last doses, within 1 hour before the second and third doses, immediately after the dose (0-1 minute after the dose), and 3-36 hours after the last dose. Blood samples were also collected from the 75 mg / kg group 4 hours, 24 hours, 48 hours, 96 hours, and 168 hours after the third dose to assess the toxicokinetics of the conjugate and its released toxin.
[0171] Table 1 below records the peak blood concentrations (C max ) and exposure (AUC). The results showed that the highest no-serious-toxicity dose (HNSTD) of conjugate A was 50 mg / kg. After the last dose of this dose, the exposure of the toxin molecule in female and male monkeys was 3.85 h*μg / mL and 5.86 h*μg / mL, respectively. The exposure of female and male monkeys to conjugate A was 45.8 h*mg / mL and 64.2 h*mg / mL, respectively.
[0172] Table 1: Peak plasma concentrations (C) of conjugate A and toxin molecules released by conjugate A in male and female monkeys max ) and exposure (AUC)
[0173] According to the test results, the exposure of ADC and toxin or C max The data are relatively close, indicating that there is no obvious toxic accumulation after continuous intravenous administration of conjugate A, and it is well tolerated in animals, with good prospects for clinical drug safety.
[0174] Example 6. In vitro metabolic stability of the conjugate
[0175] In this experiment, conjugate A and Trodelvy were firstly TM Use physiological saline to prepare 3.4 mg / mL working solution, conjugate A and Trodelvy TM The working solution was added to human blank plasma to obtain human plasma samples with a concentration of 0.05 mg / ml. The plasma samples were incubated at 37°C and the release of toxin molecules was measured at 1h, 3h, 24h, 48h, 72h and 144h to compare the release of conjugate A with the marketed drug Trodelvy.TM The results are shown in Figure 1.
[0176] Figure 1 of the specification shows that as the incubation time increases, the amount of free toxin generated in human plasma increases. After 24 hours of incubation, the amount of conjugate A and the marketed ADC drug Trodelvy in human plasma TM The percentages of toxin molecule release were 28.5% and 93.4%, respectively. After 48 hours of incubation, the concentrations of conjugate A and the marketed ADC drug Trodelvy in human plasma were significantly increased. TM The percentages of toxin molecule release were 44.6% and 109.1%, respectively. After 72 hours of incubation, the concentrations of conjugate A and the marketed ADC drug Trodelvy in human plasma were significantly increased. TM The percentages of toxin molecule release were 53.7% and 100.6%, respectively. After 144 hours of incubation, conjugate A and the marketed ADC drug Trodelvy in human plasma TM The percentages of released toxin molecules were 65.3% and 104.8%, respectively.
[0177] The results showed that the release rate of toxin molecules of conjugate A in human plasma was significantly lower than that of Trodelvy TM This indicates that conjugate A is relatively stable in human plasma, with a small amount of toxin released in plasma, effectively achieving the purpose of targeting the tumor site and then releasing the toxin. At the same time, it is similar to the marketed drug Trodelvy. TM In comparison, conjugate A can reduce the risk of serious adverse reactions caused by excessive and rapid release of toxins in plasma.
[0178] Example 7. Clinical trial
[0179] 1. Experimental Plan
[0180] Conjugate A is used to treat patients with histologically confirmed epithelial malignancies. All patients have unresectable locally advanced or metastatic solid tumors that have failed standard treatment, have no standard treatment options, or are not currently suitable for standard treatment. Based on patient weight, the dose escalation study was designed with five dose levels of 2, 4, 6, 9, and 12 mg / kg, administered intravenously every 2 weeks for a 28-day cycle until disease progression or unacceptable toxicity. The BLRM method was used to evaluate the toxicity of all planned dose groups and some intermediate dose groups. Based on model analysis, the dose escalation decision was jointly made by the sponsor and the investigator.
[0181] 2. Pharmacokinetic Studies
[0182] In the PK analysis of the dose escalation cohort, the exposure of Conjugate A increased proportionally with dose over the tested dose range of 2 to 6 mg / kg. No accumulation of Conjugate A was observed after multiple dosing. The half-lives of Conjugate A and free payload were approximately 36 hours and 49 hours, respectively, with a once-every-two-week dosing schedule. The plasma exposure of the free payload (measured as maximum plasma concentration (C max ) and area under the curve (AUC) were approximately 6% and 5% of those of conjugate A in the first 4-week cycle, respectively, while the pharmacokinetic parameters and plasma exposure of total antibody (referring to conjugated, partially unconjugated, and completely unconjugated antibodies) were similar to those of conjugate A. These results indicate that the linker of conjugate A is stable during systemic circulation and that most of the payload molecules are directed to tumor tissues by the targeting antibody.
[0183] 3. Safety Results
[0184] During the dose-escalation study, no Grade 3 or higher TEAEs occurred in the 2 mg / kg dose group; Grade 3 TEAEs, including oral mucositis and anemia, occurred in the 4 mg / kg dose group; and Grade 3 or higher TEAEs, including decreased neutrophil count and decreased white blood cell count, occurred in the 6 mg / kg dose group. Twenty-eight (93.9%) patients enrolled in the dose-escalation cohort reported TRAEs, and 17 (56.7%) experienced Grade 3 or higher TRAEs. The most common (incidence ≥ 5%) were anemia (26.7%), neutropenia (23.3%), leukopenia (16.7%), stomatitis (16.7%), and thrombocytopenia (13.3%). These Grade 3 or higher TEAEs resolved after symptomatic treatment and continued treatment. No TRAEs resulted in death. Therefore, the results of the dose-escalation study demonstrate that Conjugate A is safe and well-tolerated.
[0185] In the subsequent dose-expansion study, 211 patients received at least one dose of conjugate A. Of these, 23 and 188 patients with different types of advanced solid tumors received conjugate A at dose levels of 4 mg / kg Q2W and 5 mg / kg Q2W, respectively. TRAEs were reported in 202 (95.7%) patients. 110 (52.1%) patients reported grade 3 or higher TRAEs, most of which recovered after supportive care or dose adjustments. 51 (24.2%) patients experienced treatment-related serious adverse events (TRSAEs), and no TRAEs resulting in death were reported. This further demonstrates that the safety of conjugate A monotherapy is tolerable and manageable.
[0186] Table 2 below summarizes the TRAEs for the 4 mg / kg Q2W and 5 mg / kg Q2W dose levels.
[0187] Table 2: TRAEs at 4 mg / kg Q2W and 5 mg / kg Q2W doses
[0188] In a phase 1 / 2, multicenter, dose-escalation / expansion study in patients with relapsed or refractory locally advanced / metastatic NSCLC and other tumor types, all NSCLC patients received conjugate A at a dose of 5 mg / kg IV every 2 weeks. Tumor assessments were performed every 8 weeks based on RECIST 1.1. Among the 43 enrolled patients (63% male, 88% ECOG ps1, median age 58 years [range, 44-74]), 67.4% (29 / 43) experienced grade 3 or higher TRAEs. The most common grade 3 or higher TRAEs (incidence ≥5%) were decreased neutrophil count (32.6%), anemia (30.2%), decreased white blood cell count (WBC) (23.3%), stomatitis (9.3%), rash (7.0%), and decreased lymphocyte count (7.0%). Grade 4 TRAEs occurred only with neutropenia and leukopenia. Most hematologic toxicities occurred within the first two months of treatment and resolved with administration of granulocyte colony-stimulating factor or erythropoietin without transfusion. Dose reductions due to TRAEs occurred in 23.3% (10 of 43) of patients. No neuropathy or drug-related ILD / pneumonitis were reported. No TRAEs led to treatment discontinuation or death.
[0189] 4. Effectiveness Results
[0190] The treatment results for each indication are as follows:
[0191] 1. Triple-negative breast cancer (TNBC)
[0192] Among all patients with triple-negative breast cancer, some patients experience partial remission of their disease.
[0193] In a patient whose disease progressed after neoadjuvant chemotherapy with doxorubicin / cyclophosphamide / paclitaxel, left mastectomy, and left thoracic radiotherapy, intravenous infusion of Conjugate A at a weight-based dose of 4 mg / kg, according to the aforementioned dosing schedule, a partial response was observed after 18 weeks, which lasted for 6 weeks. Across multiple efficacy assessments, the total volume of target lesions decreased by up to 40%. No serious adverse events were reported.
[0194] 2. Ovarian cancer
[0195] Some of the patients with ovarian cancer experience a partial remission of their disease.
[0196] In an ovarian cancer patient who had previously failed multiple lines of therapy, including hysterectomy, ovarian tumor resection, carboplatin / paclitaxel, rucaparib, and carboplatin / docetaxel / bevacizumab, intravenous infusion of Conjugate A at a weight-based dose of 4 mg / kg, according to the aforementioned dosing schedule, a partial response was observed after 21 weeks, which persisted for 15 weeks. Multiple efficacy assessments demonstrated a 64.8% reduction in the total volume of target lesions, with one target lesion completely disappearing. No serious adverse events were reported.
[0197] 3. HER2-positive breast cancer
[0198] In a patient with HER2-positive breast cancer who had previously responded to modified radical mastectomy, epirubicin / paclitaxel, a HER2 monoclonal antibody / docetaxel, and capecitabine, a partial disease response was observed after eight weeks of intravenous infusion of Conjugate A at a weight-based dose of 6 mg / kg, according to the aforementioned dosing schedule. Multiple efficacy assessments demonstrated a 49.6% reduction in the total volume of target lesions.
[0199] 4. Gastric cancer
[0200] A patient with gastric cancer who had previously failed total gastrectomy, paclitaxel / Tegafur, anlotinib / Tegafur, anlotinib / capecitabine, oxaliplatin / fluorouracil, and oxaliplatin / raltitrexed received intravenous infusion of Conjugate A at a weight-based dose of 4 mg / kg, according to the aforementioned dosing schedule. A partial response was observed after 15 weeks, which has persisted for 10 weeks and is currently benefiting. Multiple efficacy assessments demonstrated a 62.8% reduction in the total volume of target lesions, with one target lesion disappearing. No serious adverse events were reported.
[0201] 5. Pancreatic cancer
[0202] In a patient with pancreatic cancer who had previously failed multiple lines of treatment including distal pancreatic resection, radiotherapy, gemcitabine / capecitabine, gemcitabine / irinotecan / fluorouracil, gemcitabine / albumin-paclitaxel / oxaliplatin / fluorouracil, and nivolumab / cabiralizumab, conjugate A was administered intravenously at a dose of 4 mg / kg based on the patient's body weight and according to the above-mentioned dosing cycle. Disease stabilization was observed after 7 weeks and lasted for 30.3 weeks. After multiple efficacy evaluations, the total volume of target lesions was reduced by 8.8%, and the patient did not experience any serious adverse events.
[0203] 6. HR+ / Her2- breast cancer
[0204] Thirty-nine patients were enrolled and treated with conjugate A. Among the 28 response-evaluable patients (those with at least one post-baseline tumor assessment), the ORR was 42.9% (12 / 28, 2 pending confirmation) and the DCR was 85.7% (24 / 28), with a median PFS of 7.6 months.
[0205] 7. Non-small cell lung cancer (NSCLC)
[0206] In this phase 1 / 2 multicenter dose-escalation / expansion study in patients with relapsed or refractory locally advanced / metastatic NSCLC and other tumor types, all NSCLC patients received 5 mg / kg IV every 2 weeks of conjugate A. Tumor assessments based on RECIST 1.1 were performed every 8 weeks.
[0207] Among the 43 enrolled patients (63% male, 88% ECOG ps1, median age 58 years [44-74]), the median follow-up was 11.5 months (95% CI, 10.4-12.2). The median duration of treatment was 5.7 months (range, 0.5-14.1). Among the 39 response-evaluable patients, the ORR was 44% (17 / 39; 15 confirmed, 2 unconfirmed), with a median duration of response of 9.3 months (range, 1.3+ to 11.2+), and a 6-month DoR rate of 77%. In the EGFR wild-type subgroup (who had received a median of two prior lines of therapy, including anti-PD-1 / L1 monoclonal antibody therapy), the ORR was 26% (5 / 19), the DCR was 89% (17 / 19), the median PFS was 5.3 months, and the 9-month OS rate was 80.4%. For the TKI-resistant EGFR-mutated NSCLC subgroup (50% also failed at least one line of chemotherapy), the ORR was 60% (12 / 20), the DCR was 100% (20 / 20), the median PFS was 11.1 months, and the 9-month PFS rate was 66.7%.
[0208] In summary, clinical trials have shown that Conjugate A exhibits promising efficacy in the treatment of unresectable locally advanced or metastatic solid tumors that have failed standard therapy, without inducing severe toxicities that could preclude clinical use. These results demonstrate that Conjugate A exhibits favorable safety and efficacy for the treatment of tumors, and that different batches of Conjugate A with DAR values ranging from 6 to 8 (e.g., DAR values of 7.3 or 7.4) exhibit essentially consistent efficacy and safety.
[0209] In addition to those described herein, various modifications of the present invention will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application (including all patents, patent applications, journal articles, books, and any other disclosures) is incorporated herein by reference in its entirety.
Claims
1. Use of a bioactive conjugate of formula (I) in the preparation of a medicament for treating individuals with recurrent or refractory locally advanced or metastatic non-small cell lung cancer; {D-[L1-(L2) m1 -(L3) m2 -(L4) m3 -E]} γ -A formula (I) in, L1 is wherein each R1 and R2 are independently hydrogen (e.g., protium or deuterium), halogen, carboxylic acid, sulfonic acid, cyano, C 1-6 Alkyl, halogenated C 1-6 Alkyl, cyano substituted C 1-6 Alkyl (e.g. -CH2CN), C 1-6 Alkoxy, C 2-10 Alkenyl or C 2-10 Alkynyl; Z1 is an amino acid or a peptide composed of 2-10 amino acids; x1 and x2 are each independently 0, 1, 2, 3, 4, 5 or 6; and the 1 position of L1 is connected to D, and the 2 position of L1 is connected to L2; L2 is Wherein, y1 is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; and the 1 position of L2 is connected to L1, and the 2 position of L2 is connected to L3; L3 is selected from a 5-12 membered heteroaromatic ring; L4 Where Z2 is selected from C 1-6 Alkylene, C 2-10 Alkenylene, C 2-10 Alkyne, and C 3-8 Cycloalkylene; R3 is selected from H and C 1-6 Alkyl; Z3 is absent or selected from C 1-6 Alkylene; or, R3 and Z3 together with the nitrogen atom to which they are connected form a 4-8 membered heterocyclic group; α is 0, 1, 2, 3, 4, 5 or 6, and the 2 position of L4 is connected to E, and the 1 position of L4 is connected to L3; E is wherein each R4 is independently hydrogen (e.g., protium or deuterium), β is 0, 1 or 2, and the 2 position of E is connected to A (e.g., connected to the thiol group on A), and the 1 position of E is connected to L4; m1, m2 and m3 are each independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; D is a bioactive molecular fragment; γ is selected from an integer between 1 and 10; preferably, γ is selected from an integer between 3 and 8 (e.g., 3, 4, 5, 6, 7 or 8); A is an anti-Trop-2 monoclonal antibody or an antigen-binding fragment thereof.
2. The use according to claim 1, wherein the non-small cell lung cancer is unresectable locally advanced or metastatic non-small cell lung cancer that has failed standard treatment, or has no standard treatment options, or is not currently suitable for standard treatment.
3. The use according to claim 1 or 2, wherein the non-small cell lung cancer is EGFR wild-type non-small cell lung cancer.
4. The use according to claim 3, wherein the individual has previously received a median of 2 lines of treatment.
5. The use according to claim 3, wherein the individual has previously received platinum-containing chemotherapy combined with anti-PD-1 / L1 monoclonal antibody treatment.
6. The use according to claim 1 or 2, wherein the non-small cell lung cancer carries an EGFR mutation, preferably, the EGFR mutation includes exon 19 deletion or exon 21 L858R mutation.
7. The use according to claim 6, wherein the NSCLC individual carrying the EGFR mutation has previously received first-generation or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment, and after treatment failure, tumor biopsy confirmed that the exon 20 T790M mutation is negative, or the NSCLC individual carrying the EGFR mutation has previously received third-generation EGFR-TKI treatment, regardless of whether the T790M mutation exists.
8. The use according to claim 6 or 7, wherein the non-small cell lung cancer is resistant to EGFR-TKI treatment.
9. The use according to any one of claims 6 to 8, wherein the individual has received first-line treatment, preferably, the first-line treatment is platinum-containing chemotherapy.
10. The use according to any one of claims 1 to 9, wherein the conjugate has the following structure: L1 is selected from And the 1 position of L1 is connected to D, and the 2 position of L1 is connected to L2; L2 is in, y1 is 3, 4, 5, 6, 7, 8, 9 or 10; and the 1 position of L2 is connected to L1, and the 2 position of L2 is connected to L3; L3 is selected from a 5-6 membered heteroaromatic ring, such as pyrazole or triazole; L4 Where Z2 is selected from C 1-3 Alkylene; R3 is H; Z3 is selected from C 1-3 Alkylene; α is 1, and the 2-position of L4 is connected to E, and the 1-position of L4 is connected to L3; E is wherein each R4 is independently hydrogen (e.g., protium or deuterium), β is 0, 1 or 2, and the 2 position of E is connected to A (e.g., connected to the thiol group on A), and the 1 position of E is connected to L4; m1, m2 and m3 are all 1; The bioactive molecule is selected from Preferably, the bioactive molecule is connected to the 1 position of L1 through its own hydroxyl group; γ is selected from an integer between 3 and 8 (e.g., 3, 4, 5, 6, 7 or 8); A is Sacituzumab or an antigen-binding fragment thereof.
11. The use according to any one of claims 1 to 10, wherein the conjugate has the following structure: in, γ is an integer of 1-10; preferably, γ is an integer selected from 5-8.
12. A method for treating recurrent or refractory locally advanced or metastatic non-small cell lung cancer, the method comprising the step of administering to an individual in need thereof a therapeutically effective amount of a bioactive conjugate as described in any one of claims 1, 10-11 and / or a pharmaceutical composition comprising a bioactive conjugate as described in any one of claims 1, 10-11.
13. The method according to claim 12, wherein the non-small cell lung cancer is unresectable locally advanced or metastatic non-small cell lung cancer that has failed standard treatment, or has no standard treatment options, or is not currently suitable for standard treatment.
14. The method according to claim 12 or 13, wherein the non-small cell lung cancer is EGFR wild-type non-small cell lung cancer.
15. The use according to claim 14, wherein the subject has previously received a median of 2 lines of therapy.
16. The method of claim 14, wherein the individual has previously received platinum-containing chemotherapy combined with anti-PD-1 / L1 monoclonal antibody therapy.
17. The method according to claim 12 or 13, wherein the non-small cell lung cancer carries an EGFR mutation, preferably, the EGFR mutation comprises an exon 19 deletion or an exon 21 L858R mutation.
18. The method according to claim 17, wherein the NSCLC individual carrying the EGFR mutation has previously received treatment with a first-generation or second-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), and after treatment failure, a tumor biopsy confirmed that the exon 20 T790M mutation was negative, or the NSCLC individual carrying the EGFR mutation has previously received treatment with a third-generation EGFR-TKI, regardless of the presence of a T790M mutation.
19. The method of claim 17 or 18, wherein the non-small cell lung cancer is resistant to EGFR-TKI treatment.
20. The method of claim 19, wherein the individual has received first-line treatment, preferably, the first-line treatment is platinum-containing chemotherapy.
21. The method according to any one of claims 12 to 20, wherein the pharmaceutical composition comprises the bioactive substance conjugate and a pharmaceutically acceptable carrier and / or excipient.
22. The method according to any one of claims 12 to 21, wherein the bioactive conjugate or the pharmaceutical composition is administered once every 7 to 35 days, preferably once every 7 to 28 days, for example once every 7 days, 14 days, 21 days, 28 days, or 35 days.
23. The method according to any one of claims 12 to 22, wherein the bioactive substance conjugate or the pharmaceutical composition is administered once every 14 days.
24. The method according to any one of claims 12 to 23, wherein the conjugate or pharmaceutical composition is administered orally, percutaneously, rectally, transmucosally, intramuscularly, intramedullary, intravenously, or intraperitoneally, preferably intravenously.
25. The method according to any one of claims 12-24, wherein the dosage of the bioactive substance conjugate per administration is 1 mg / kg to 30 mg / kg based on individual body weight; preferably 1 mg / kg to 20 mg / kg; more preferably 2 mg / kg to 12 mg / kg; further preferably 2-5 mg / kg, 4-7 mg / kg, 6-9 mg / kg, 8-11 mg / kg, 10-13 mg / kg, or 12-15 mg / kg.
26. The method according to any one of claims 12 to 25, wherein the dosage of the bioactive substance conjugate administered each time is 4 mg / kg or 5 mg / kg based on the individual's body weight.
27. The method according to any one of claims 12 to 26, wherein the dosage of the bioactive substance conjugate or the composition thereof is 1 mg / kg to 20 mg / kg based on the individual's body weight, and is administered once every 7 to 28 days.
28. The method according to any one of claims 12-27, which is divided into one or more administration stages (e.g., one, two, three or four stages), the administration cycle of each stage is as described in any one of claims 22, 23, 27, and / or the administration dose of each stage is as described in any one of claims 25-27.
Citation Information
Patent Citations
Antibody, and conjugate and preparation method and purpose thereof
CN110903395A
Novel thiol & amino modifying reagents for protein chemistry and methods of use thereof
WO2014144878A2
Bioactive conjugate, preparation method therefor and use thereof
WO2019114666A1
Use of medicament in treatment of tumor disease
WO2022228497A1
Combined use of Anti-trop-2 antibody-drug conjugate and other therapeutic agents
WO2023134706A1
